Eisai Co., Ltd. (4523.T) Stock Analysis

Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias

Mon, June 1, 2026 at 11:00 AM UTC 3 min read

Eisai Co., Ltd. (4523.T) has partnered with CaringKind to launch a new initiative aimed at addressing the mealtime and nutrition needs of individuals living with Alzheimer's disease and related dementias. This collaboration highlights Eisai's commitment to improving patient care, which could enhance its reputation and market position in the Alzheimer's treatment sector. Investors may view this initiative as a positive step towards expanding Eisai's influence in a growing healthcare market focused on dementia-related solutions.

Read full article →

Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)

Fri, May 15, 2026 at 6:59 AM UTC 3 min read

Eisai has announced a projected revenue of JPY 143.5 billion for its Alzheimer's drug, Leqembi®, for the fiscal year 2026. This projection is significant for investors as it highlights the company's confidence in Leqembi's market potential and growth trajectory, which could positively impact Eisai's overall financial performance and stock valuation. Investors will be closely monitoring the drug's adoption and sales trends leading up to this forecasted period.

Read full article →